$Vaxart (VXRT.US)$ Vaxart, Inc. (NASDAQ: VXRT) reported its ...

Vaxart, Inc. (NASDAQ: VXRT) reported its Q2 2024 financial results and provided a business update. Key highlights include:

1. BARDA awarded Vaxart up to $453 million for a Phase 2b trial of its oral COVID-19 vaccine.

2. The company plans to initiate the 10,000-subject Phase 2b trial in H2 2024, pending FDA alignment.

3. Vaxart is in discussions with the FDA regarding norovirus vaccine data and potential next steps.

4. Q2 2024 financial results: $62.6 million in cash and investments, $6.4 million in revenue, and a net loss of $16.5 million ($0.09 per share).

5. The company received a $64.7 million BARDA payment post-Q2, extending cash runway into 2026.